Tags

Type your tag names separated by a space and hit enter

Cross-protective immunity against multiple influenza virus subtypes by a novel modified vaccinia Ankara (MVA) vectored vaccine in mice.
Vaccine. 2013 Apr 03; 31(14):1848-55.V

Abstract

Development of an influenza vaccine that provides cross-protective immunity remains a challenge. Candidate vaccines based on a recombinant modified vaccinia Ankara (MVA) viral vector expressing antigens from influenza (MVA/Flu) viruses were constructed. A vaccine candidate, designated MVA/HA1/C13L/NP, that expresses the hemagglutinin from pandemic H1N1 (A/California/04/09) and the nucleoprotein (NP) from highly pathogenic H5N1 (A/Vietnam/1203/04) fused to a secretory signal sequence from vaccinia virus was highly protective. The vaccine elicited strong antibody titers to homologous H1N1 viruses while cross-reactive antibodies to heterologous viruses were not detectable. In mice, this MVA/HA1/C13L/NP vaccine conferred complete protection against lethal challenge with A/Vietnam/1203/04 (H5N1), A/Norway/3487-2/09 (pandemic H1N1) or A/Influenza/Puerto Rico/8/34 (seasonal H1N1) and partial protection (57.1%) against challenge with seasonal H3N2 virus (A/Aichi/68). The protective efficacy of the vaccine was not affected by pre-existing immunity to vaccinia. Our findings highlight MVA as suitable vector to express multiple influenza antigens that could afford broad cross-protective immunity against multiple subtypes of influenza virus.

Authors+Show Affiliations

Inviragen, Inc., 6502 Odana Rd, Madison, WI 53719, USA. jbrewoo@inviragen.comNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Research Support, N.I.H., Extramural

Language

eng

PubMed ID

23376279

Citation

Brewoo, Joseph N., et al. "Cross-protective Immunity Against Multiple Influenza Virus Subtypes By a Novel Modified Vaccinia Ankara (MVA) Vectored Vaccine in Mice." Vaccine, vol. 31, no. 14, 2013, pp. 1848-55.
Brewoo JN, Powell TD, Jones JC, et al. Cross-protective immunity against multiple influenza virus subtypes by a novel modified vaccinia Ankara (MVA) vectored vaccine in mice. Vaccine. 2013;31(14):1848-55.
Brewoo, J. N., Powell, T. D., Jones, J. C., Gundlach, N. A., Young, G. R., Chu, H., Das, S. C., Partidos, C. D., Stinchcomb, D. T., & Osorio, J. E. (2013). Cross-protective immunity against multiple influenza virus subtypes by a novel modified vaccinia Ankara (MVA) vectored vaccine in mice. Vaccine, 31(14), 1848-55. https://doi.org/10.1016/j.vaccine.2013.01.038
Brewoo JN, et al. Cross-protective Immunity Against Multiple Influenza Virus Subtypes By a Novel Modified Vaccinia Ankara (MVA) Vectored Vaccine in Mice. Vaccine. 2013 Apr 3;31(14):1848-55. PubMed PMID: 23376279.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Cross-protective immunity against multiple influenza virus subtypes by a novel modified vaccinia Ankara (MVA) vectored vaccine in mice. AU - Brewoo,Joseph N, AU - Powell,Tim D, AU - Jones,Jeremy C, AU - Gundlach,Nancy A, AU - Young,Ginger R, AU - Chu,Haiyan, AU - Das,Subash C, AU - Partidos,Charalambos D, AU - Stinchcomb,Dan T, AU - Osorio,Jorge E, Y1 - 2013/02/01/ PY - 2012/08/14/received PY - 2013/01/19/revised PY - 2013/01/21/accepted PY - 2013/2/5/entrez PY - 2013/2/5/pubmed PY - 2014/2/13/medline SP - 1848 EP - 55 JF - Vaccine JO - Vaccine VL - 31 IS - 14 N2 - Development of an influenza vaccine that provides cross-protective immunity remains a challenge. Candidate vaccines based on a recombinant modified vaccinia Ankara (MVA) viral vector expressing antigens from influenza (MVA/Flu) viruses were constructed. A vaccine candidate, designated MVA/HA1/C13L/NP, that expresses the hemagglutinin from pandemic H1N1 (A/California/04/09) and the nucleoprotein (NP) from highly pathogenic H5N1 (A/Vietnam/1203/04) fused to a secretory signal sequence from vaccinia virus was highly protective. The vaccine elicited strong antibody titers to homologous H1N1 viruses while cross-reactive antibodies to heterologous viruses were not detectable. In mice, this MVA/HA1/C13L/NP vaccine conferred complete protection against lethal challenge with A/Vietnam/1203/04 (H5N1), A/Norway/3487-2/09 (pandemic H1N1) or A/Influenza/Puerto Rico/8/34 (seasonal H1N1) and partial protection (57.1%) against challenge with seasonal H3N2 virus (A/Aichi/68). The protective efficacy of the vaccine was not affected by pre-existing immunity to vaccinia. Our findings highlight MVA as suitable vector to express multiple influenza antigens that could afford broad cross-protective immunity against multiple subtypes of influenza virus. SN - 1873-2518 UR - https://www.unboundmedicine.com/medline/citation/23376279/Cross_protective_immunity_against_multiple_influenza_virus_subtypes_by_a_novel_modified_vaccinia_Ankara__MVA__vectored_vaccine_in_mice_ L2 - https://linkinghub.elsevier.com/retrieve/pii/S0264-410X(13)00106-0 DB - PRIME DP - Unbound Medicine ER -